SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-19-011587
Filing Date
2019-02-28
Accepted
2019-02-28 16:50:17
Documents
1
Group Members
BARBARA N. LUBASHBRADLEY J. BOLZONBRIAN G. ATWOODCHARLES M. WARDENDONALD B. MILDERREBECCA B. ROBERTSONROBIN L. PRAEGERROSS A. JAFFESAMUEL D. COLELLAVERSANT SIDE FUND III, L.P.VERSANT VENTURES III, LLCWILLIAM J. LINK

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a19-4717_4sc13da.htm SC 13D/A 395830
  Complete submission text file 0001104659-19-011587.txt   397985
Mailing Address 601 GATEWAY BOULEVARD SUITE 250 SOUTH SAN FRANCISCO CA 94080
Business Address 1616 EASTLAKE AVENUE E. SUITE 310 SEATTLE WA 98102 (650) 392-8350
IMMUNE DESIGN CORP. (Subject) CIK: 0001437786 (see all company filings)

IRS No.: 262007174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88256 | Film No.: 19644223
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 650-233-2211
Versant Venture Capital III, L.P. (Filed by) CIK: 0001456586 (see all company filings)

IRS No.: 203659276 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A